| Literature DB >> 35417966 |
G N Chennakeshavallu1, Shrinivas Gadhinglajkar1, Rupa Sreedhar1, Saravana Babu1, Sruthi Sankar1, Prasanta Kumar Dash1.
Abstract
Background: Assessment of myocardial deformation by quantifying peak systolic longitudinal strain (PSLS) is a sensitive and robust index to detect subclinical myocardial dysfunction. We hypothesize that sevoflurane by virtue of anesthetic preconditioning preserves myocardial function better than propofol. Aims: The authors have assessed the effects of sevoflurane and propofol on global longitudinal strain (GLS) as a primary outcome in patients undergoing on-pump coronary artery bypass grafting. Our secondary aim was to assess the pattern of regional distribution of segmental PSLS between the groups. Materials andEntities:
Keywords: Coronary artery bypass grafting; propofol; sevoflurane; strain imaging; transesophageal echocardiography
Mesh:
Substances:
Year: 2022 PMID: 35417966 PMCID: PMC9244250 DOI: 10.4103/aca.aca_240_20
Source DB: PubMed Journal: Ann Card Anaesth ISSN: 0971-9784
Figure 1Representative 2D longitudinal strain imaging depicting GLS and segmental PSLS. The time–longitudinal strain curves for the ME-4ch (a), 2-ch (b), and 3-ch (c) views are displayed. In (d), the bull's eye plot displays the regional value of PSLS for 17 segments and the LV GLS is averaged. Abbreviations: PSLS: peak systolic longitudinal strain, GLS: Global longitudinal strain.
Patient characteristics
| Parameter | S-Group ( | P-group ( | |
|---|---|---|---|
|
| |||
| Preoperative data | |||
| Age (years) | 59.27±9.84 | 61.46±9.01 | 0.417 |
| Sex, F/M | 7/19 | 5/19 | 0.628 |
| Body mass index (kg/m2) | 22.4±4.2 | 20.3±4.3 | 0.15 |
| Diabetes | 20 (77%) | 18 (75%) | 0.869 |
| Hypertension | 14 (53%) | 19 (79%) | 0.055 |
| NYHA I/II/III/IV | 0/19/7/0 | 0/19/5/0 | 0.6187 |
|
| |||
|
| |||
|
| |||
| LMCA>70% stenosis | 0 | 0 | |
| LAD>70% stenosis | 25 | 24 | 0.336 |
| LCX>70% stenosis | 18 | 20 | 0.253 |
| RCA>70% stenosis | 24 | 20 | 0.338 |
|
| |||
|
| |||
|
| |||
| No of venous bypass grafts (median) | 3 (2-4) | 3 (2-4) | 1 |
| No. of arterial grafts (median) | 1 | 1 | 1 |
| Aortic cross clamp (min) | 45.76±5.399 | 46.53±6.28 | 0.643 |
| CPB time (min) | 107.56±13.87 | 111.65±12.86 | 0.286 |
|
| |||
|
| |||
|
| |||
| Ejection fraction (%) | 53.1±4.70 | 54.7±5.10 | 0.7741 |
| Wall motion score | 1.21±0.22 | 1.15±0.23 | 0.3506 |
| Cardiac index (L/m2) | 2.8±0.64 | 2.8±0.58 | 1 |
| Lateral S′ velocity (m/s) | 6.09±1.41 | 6.59±1.05 | 0.1642 |
| GLS | −16.02±4.90 | −15.45±5.03 | 0.6867 |
Data presented as mean±SD, number/percentage and median (range). Unpaired t test and Fisher’s exact test were applied
Pre- and post-CPB comparison of GLS and segmental PSLS in both the groups
| Strain | Sevoflurane ( | Propofol ( | ||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Pre-CPB (mean, SD) | Post-CPB (mean, SD) |
| Pre-CPB (mean, SD) | Post-CPB (mean, SD) |
| |
| BA | −11.53, 4.55 | −12.16, 4.67 | 0.6390 | −12.33, 3.85 | −11.17, 3.58 | 0.2970 |
| BAS | −10.96, 4.24 | −10.68, 3.81 | 0.8124 | −11, 4.38 | −9.28, 3.43 | 0.0937 |
| BIS | −12.53, 3.78 | −11.78, 5.37 | 0.5682 | −12.70, 4.01 | −10.08, 5.03 | 0.0562 |
| BI | −14.30, 4.97 | −12.56, 6.17 | 0.2759 | −11.83, 5.41 | −10.60, 4.69 | 0.4164 |
| BIL | −13.38, 4.88 | −13.72, 5.31 | 0.8110 | −14.08, 5.28 | −12.90, 4.58 | 0.4244 |
| BAL | −14.03, 4.76 | −14.27, 6.55 | 0.8821 | −14, 4.31 | −12.37, 6.35 | 0.3104 |
| MA | −14.73, 4.78 | −12.36, 5.38 | 0.1056 | −15.54, 6.37 | −14.09, 8.62 | 0.5174 |
| MAS | −15.50, 5.51 | −14.16, 7.77 | 0.4825 | −15.16, 4.99 | −10.91, 4.35 | 0.0037* |
| MIS | −15.53, 3.84 | −13.17, 5.44 | 0.0768 | −13.62, 4.98 | −10.70, 5.66 | 0.0666 |
| MI | −16.29, 5.11 | −14.57, 4.36 | 0.1977 | −15.54, 6.57 | −11.36, 3.68 | 0.0022* |
| MIL | −14.73, 4.92 | −13.95, 7.03 | 0.1096 | −16.37, 6.92 | −12.69, 4.86 | 0.0412* |
| MAL | −14.69, 5.19 | −12.47, 5.80 | 0.1070 | −19.79, 6.75 | −11.75, 4.55 | <0.0001* |
| AA | −16.19, 4.26 | −13.92, 4.47 | 0.0722 | −17, 5.64 | −14.37, 6.21 | 0.1352 |
| AS | −17.69, 5.02 | −11.39, 3.71 | 0.0005* | −19.25, 7.15 | −14.33, 6.47 | 0.0174* |
| AI | −17.92, 4.90 | −13.96, 4.85 | 0.0061* | −16.83, 4.89 | −13.45, 5.15 | 0.0025* |
| AL | −19.34, 5.16 | −15.16, 7.10 | 0.0206* | −18.54, 4.86 | −14.04, 5.96 | 0.0067* |
| Apex | −17.84, 5.94 | −13.61, 5.76 | 0.0012* | −18.54, 5.74 | −11.54, 5.00 | 0.0001* |
| GLS | −13.38, 3.72 | −11.46, 2.74 | 0.0051* | −14.75, 3.24 | −11.93, 3.11 | <0.0001* |
* represents statistically significant decrease in regional PSLS (P< 0.05). Data expressed as mean±SD. Paired t-test was applied to compare pre- and post-CPB values. Abbreviations: BA: basal anterior, BAS: basal anterioseptal, BIS: basal inferoseptal, BI: basal inferior, BAL: basal anterolateral, MA: mid anterior, MAS: mid anteroseptal, MIS: mid inferoseptal, MI: mid inferior, MIL: mid inferolateral, MAL: mid anterolateral, AA: apical anterior, AS: apical septal, AI: apical inferior, AL: apical anterior, GLS: global longitudinal strain, PSLS: peak systolic longitudinal strain
Figure 2Left ventricular segmental changes in myocardial longitudinal strain (17-segment model) in S- and P-group. The mean difference in segmental longitudinal strain values between pre- and post-CPB period is displayed in each segment. *Represents statistically significant decrease in longitudinal strain from pre- to post-CPB period (P < 0.05).
Intergroup comparison of GLS and segmental PSLS between the groups
| Pre -CPB | Post-CPB | |||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Sevoflurane | Propofol |
| Sevoflurane | Propofol |
| |
| GLS | −13.38% ± 3.72 | −14.75% ± 3.24 | 0.2155 | −11.69% ± 2.76 | −11.93% ± 3.11 | 0.4874 |
| Basal segments PSLS | −12.03±3.15 | −13.37±2.33 | 0.1473 | −11.73±2.60 | −12.14% ± 2.18 | 0.7731 |
| Mid segments PSLS | −13.15±3.28 | −14.25±2.81 | 0.3653 | −12.19±3.25 | −12.90±2.59 | 0.6593 |
| Apical segments PSLS | −17.30±3.08 | −18.29±3.329 | 0.4071 | −14.44±3.39 | −14.13±4.32 | 0.3638 |
Data expressed as mean±SD. Unpaired t-test was applied
Postoperative parameters between the groups
| Parameter | Sevoflurane ( | Propofol ( |
|
|---|---|---|---|
| Vasoactive inotropic score | 5.19±3.15 | 5.52±3.53 | 0.5242 |
| Mechanical ventilation duration (h) | 5.17±1.82 | 6.12±2.15 | 0.6283 |
| Duration of inotropic support | 24.19±14.20 | 28.39±13.29 | 0.2099 |
Data presented as mean±SD. Unpaired t-test was applied
Intraobserver and interobserver variability of GLS and segmental PSLS
| Longitudinal strain | Pre-CPB strain (95% CI) | Post-CPB strain (95% CI) |
|---|---|---|
| Intraobserver | ||
| GLS | 0.78 (0.64-0.80) | 0.74 (0.60-0.76) |
| Basal segments PSLS | 0.78 (0.67-0.75) | 0.73 (0.61-0.78) |
| Mid segments PSLS | 0.79 (0.68-0.81) | 0.73 (0.64-0.79) |
| Apical segments PSLS (apex) | 0.81 (0.70-0.83) | 0.75 (0.72-0.80) |
| Interobserver | ||
| GLS | 0.65 (0.55-0.73) | 0.60 (0.53-0.73) |
| Basal segments PSLS | 0.55 (0.42-0.69) | 0.52 (0.44-0.66) |
| Mid segments PSLS | 0.69 (0.55-0.80) | 0.66 (0.53-0.76) |
| Apical segments PSLS (apex) | 0.70 (0.58-0.78) | 0.65 (0.55-0.74) |
Data presented as intraclass correlation coefficient (95% CIs) for global and segmental longitudinal strain at pre- and post-CPB period